Mike Krams

Dr. Krams leads clinical development strategy for Exscientia’s portfolio of investigational medicines with a focus on innovative clinical trial design and improved methods of patient selection to maximise clinical success and patient benefit. He is based at Exscientia's precision medicine centre of excellence in Vienna, Austria. Prior to joining Exscientia, Dr. Krams most recently led the Quantitative Sciences group at Janssen R&D, bringing together approximately 500 statisticians, pharmacologists and modellers to enable efficient decision-making in various aspects of drug development. Earlier, he was Vice President of Adaptive Trials and Applied Program Strategies at Wyeth. Dr. Krams holds an M.D. from the University of Munich.